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The aim of this study was to assess the feasibility of sparing contralateral hippocampus during partial brain
radiotherapy in high grade gliomas. 20 previously treated patients were replanned to 60 Gy in 30 fractions with
sparing intensity-modulated radiotherapy (IMRT) and volumetric modulated arctherapy (VMAT) using the following
planning objectives: 100 % of PTV covered by 95% isodose without violating organs at risk (OAR) and hot spot dose
constraints. For each, standard intensity-modulated radiotherapy (IMRT) plans were generated, as well as sparing
IMRT and VMAT plans which spared contralateral (hemispheric cases) hippocampus. When the three plans were
compared, there was equivalent PTV coverage, homogeneity, and conformality. Sparing IMRT significantly reduced
maximum, mean, V20, V30 and V40 hippocampus doses compared with standart IMRT and VMAT (p < 0.05). VMAT
significantly reduced maximum left lens and mean eye doses compared with standart IMRT and sparing IMRT
(p < 0.05). Brainstem, chiasm, left and right optic nerves, right eyes and lens doses were similar. VMAT significantly
reduced monitor units compared with standart IMRT and sparing IMRT (p < 0.05). It is possible to spare contralateral
hippocampus during PBRT for high grade gliomas using IMRT. This approach may reduce late cognitive sequelae of
cranial radiotherapy.
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The prognosis of the patients with high grade gliomas
had improved with the combination of radiotherapy and
chemotherapy. While expected life time has improved,
the ratio of late side effects of radiotherapy has also in-
creased (Stupp et al. 2009). Side effects are more fre-
quent in children after partial brain radiotherapy
(PBRT). These side effects include cognitive dysfunc-
tions, endocrine dysfunctions, visual loss, hearing loss,
myelopathy, vasculopathies and the induction of secondary
tumours including gliomas (high and low grade), sarcomas
and meningiomas (Merchant et al. 2005; Nandagopal et al.
2008; Kondoh et al. 2003; Douw et al. 2009; Crossen et al.* Correspondence: dremocan@ktu.edu.tr
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in any medium, provided the original work is p1994; Kortmann et al. 2003) Clear dose–volume relation-
ships exist for many of these late adverse events. However,
no clear dose–response relationships have been proven for
cognitive dysfunction and secondary tumour induction
(Merchant et al. 2005; Marks et al. 1981). These side effects
are seen less often in elderly patients (Douw et al. 2009).
Nevertheless, without necrosis, radiation induced cognitive
dysfunction and leuko-encephalopathy are the most often
complications in patients with long-term survival (Crossen
et al. 1994). This clinical presentation is different than radi-
ation necrosis in terms of clinic-radiology and pathology.
The most clinically dramatic side effect is radiation induced
dementia, and it is characterized by memory loss, attention
deficit and emotional changes (Armstrong et al. 1995;
Vigliani et al. 1997). Frequent memory loss and other
cognitive deficits are induced by radiotherapy in the
hippocampus and limbic system. According to clinicalis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Patient and tumor characteristic

















Contralateral hippocampal volume cm3
Median 2.6
Range 1.9-3.4
Canyilmaz et al. SpringerPlus  (2015) 4:114 Page 2 of 7and pre-clinical study results, the key role of neurocog-
nitive deficit pathogenesis induced by cranial radiother-
apy takes place in the neural stem cell compartment of
the hippocampus (Raber et al. 2004; Nagai et al. 2000;
Peissner et al. 1999; Roman and Sperduto 1995). The
hippocampus is a paired brain structure, located in the
ventromedial part of the temporal lobes, laying lateral to the
temporal horn of the lateral ventricle. Bilateral and unilateral
radiation injury of the hippocampus is known to alter learn-
ing and memory formation (Tofilon and Fike 2000). Clinical
data defining a clear dose–response effect does not exist but
there is a suggestion that more than 30 Gy to the temporal
lobe may be relevant (Armstrong et al. 2010).
Intensity modulated radiotherapy (IMRT) can allow
dosage increase in high grade gliomas as well as reduce
late toxicity due to radiotherapy. According to a retro-
spective analysis that compared IMRT with conformal
radiation therapy, IMRT provided equal overall survival
without prognosis change, and it decreases acute and
late neurotoxicity (Merchant et al. 2005). In dosimetric
studies of high grade gliomas, when IMRT is compared
with three-dimensional conformal irradiation, IMRT is su-
perior in limiting exposure for organs at risk (OAR) and
allows for the planned target volume coverage (Narayana
et al. 2006; MacDonald et al. 2007). As an extension of
IMRT, volumetric modulated arc therapy (VMAT) is cur-
rently in use for the treatment of many cancers. Gantry
arc-based IMRT delivery methods involve the gantry
rotating around the patient while the multileaf collima-
tor (MLC) leaf positions, dose rate and gantry speed
are varied simultaneously (Otto 2008).
This current dosimetric study was conducted to evalu-
ate the preservability of the contralateral hippocampus,
in case of ipsilateral hippocampus invasion by a tumor
during PBRT in high grade hemispheric gliomas.
Methods and materials
We identified 20 patients with high-grade glioma who
previously have been treated in our department with
PBRT. Patient and tumor characteristics are shown in
Table 1. In our study, we used CT scans of 20 patients
diagnosed with hemispheric high grade glioma in our
clinic after approval of ethical committee. Patients were
immobilized in the supine position using an individual-
ized thermoplastic mask. CT and magnetic resonance
imaging scans were performed, both with a 2.5-mm slice
thickness, and were used to aid tumor delineation. We
reloaded CT scans that were used in the treatment of
the patients and archived in CT-simulator into the
Eclipse treatment planning system. Target volume and
OAR identified in the CT scans of all patients were con-
toured by a radiation oncologist to prevent personal
contouring differences that could skew the study results.
Two researchers, one of which is a radiologist, evaluatedthe contouring. We made IMRT planning suitable to
dosage constraints in our study using Eclipse TPS in
our department. Afterwards, CT scans were transferred
to another treatment center to make VMAT planning.
For each patient, two intensity-modulated radiotherapy
treatment plans and VMAT plans were generated using
the eclipse Version 10.1 treatment planning system. All
IMRT and VMAT plans were generated using 6-mv for a
linear accelerator and 120-leaf multileaf collimator (MLC)
(5-mm width leaves over target extent). For both tech-
niques, final dose calculations were performed using the
single pencil beam algorithm in Eclipse. The DVH calcula-
tions were also performed in Eclipse.
The standart IMRT plan, designated standard, did not
include hippocampus as avoidance structures in optimisa-
tion criteria. The sparing IMRT and VMAT plans, desig-
nated sparing, did introduce hippocampus as avoidance
structures. Optic nerve, chiasma, brain stem, eyes and
lenses were the structures contoured in the study as OAR.
The hippocampus was contoured on T1-weighted MRI
axial sequences. The contralateral hippocampus was con-
toured by the reference of Gondi et al (Gondi et al. 2010).
The baseline optimisation criteria for the high grade gli-
oma cases are shown in Table 2.
In the traditional IMRT and VMAT plans, the prescrip-
tion dose for phase I was 46Gy in 23 fractions delivered to
PTV 46Gy, followed by a sequential cone down boost of
14Gy in seven fractions delivered to PTV 60Gy. For all
Table 2 Baseline optimization criteria for all plans
Structure Optimisation criteria
Initial phase (46 Gy in 23 fractions to PTV 46 Gy)
PTV 46 Gy 95% to receive 46 Gy
Right eye 0% to receive 30 Gy
Left eye 0% to receive 30 Gy
Right lens 0% to receive 6 Gy
Left lens 0% to receive 6 Gy
Right optic nerve 0% to receive 42 Gy
Left optic nerve 0% to receive 42 Gy
Optic chiasm 0% to receive 42 Gy
Brainstem 0% to receive 42 Gy
Hippocampus 0% to receive 15 Gy
Boost phase (14 Gy in seven fractions to PTV 60 Gy)
PTV 60 Gy 95% to receive 14 Gy
Right eye 0% to receive 5 Gy
Left eye 0% to receive 5 Gy
Right lens 0% to receive 4 Gy
Left lens 0% to receive 4 Gy
Right optic nerve 0% to receive 12 Gy
Left optic nerve 0% to receive 12 Gy
Optic chiasm 0% to receive 12 Gy
Brainstem 0% to receive 12 Gy
Hippocampus 0% to receive 5 Gy
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tumor volume (GTV) (gross enhancing tumour and resec-
tion cavity as identified on postoperative MRI T1 post-
contrast sequences), peri- tumouraloedema (as identified
on postoperative MRI T2 fluid attenuated inversion recov-
ery sequences), clinical treatment volume (CTV) 46Gy
(GTV + peri-tumouraloedema + 2-cm anatomically con-
strained margins), PTV46Gy (CTV 46Gy + 5-mm margin),
CTV 60Gy in IMRT plans (GTV + anatomically con-
strained 2-cm margin), PTV 60Gy in IMRT plans
(CTV60Gy + 5-mm margin) (Chang et al. 2007; Nelson
et al. 1993). Two different IMRT plans were performed for
standart and sparing IMRT.The first IMRT plan set used
seven beams (0°,51°,102°,153°,204°,255°,306°) isocentrically
centered on the PTV for PTV 46. The second IMRT plan
set used five beams isocentrically centered on the PTV
for PTV 60. Five field IMRT plan special to each pa-
tient with angles according to the tumor location. All
beams were collimatedt o minimize exposure to the
hippocampus. The dose homogeneity goal was < 110°
within the PTV. Achieve at least 100% coverage of PTV
with the 95% isodose of 46 and 60 Gy without violating
OAR maximum dose constraints.
The VMAT plans were generated using an in-house
inverse planning approach, in which MLC-shaped fieldswere progressively added throughout a single 360 arc
during optimization. The dose rate was between 0 and
600MU/min and gantry rotation between 0.0°/s and a
maximum of 4.8°/s. The collimator was rotated to about
45° to 315° to minimize the contribution of the tongue-
and Groove effect during treatment. The MLC con-
straints are included in the optimization, ensuring that
the plan is always deliverable. Inhomogeneity corrections
were not implemented for this in-house planning system
and were therefore not used during optimization or final
dose calculation. In VMAT planning, we used 2 arc plan
to decide the most suitable treatment plan for PTV46 and
PTV60. After failing to obtain dose homogeneity for PTV,
we made 1 arc and 3 arc VMAT plans. As a result, we de-
cided to use 2 arc VMAT planning because of highest PTV
homogeneity. Both for PTV 46 and PTV 60; we used 45°
collimation between 182°-178°, 178°-182° angles for the
planning of patients with right hemispheric localization.
We used 45°collimation between 178°-182° and 182°-178,
for planning of patients with left hemispheric localization.
Evaluation of treatment plans
A comparative analysis was then performed using the
twenty computed tomography data sets. Dosimetric pa-
rameters were evaluated for target volumes and OARs.
For PTV, the comparison parameters included maximum
dose (D max), mean dose (D mean), D95%, conformality
index (CI), and homogeneity index (HI). We evaluated D
mean and D max for the hippocampus, Dmax dose for
lens, eyes, optic nerves, brain stem, and chiasm for OARs.
The CI of the PTV was defined as:
CI ¼ VPTVx VTV=TVPV2
V
PTV
: Treatment volume for identified isodose, V
TV
: Volume of PTV,
TV
PV
2: Volume of PTV inside of treatment volume for identified
isodose.
The HI of the PTV was defined by using this formula:
HI ¼ D5%=D95%
D5%; Dose received by 5% of PTV, D95% Dose received
by 95% of PTV (Ding et al. 2006; Lee et al. 2012).
Statistical analysis
Dose-volume histograms (DVH) were used in the com-
parison of the target volume and at-risk organ doses in all
the treatment plans. In the comparison of the data, if para-
metric conditions were provided, ANOVA post hoc was
used, otherwise, the Kruskal-Wallis Test was used. In the
paired group comparisons of quantifiable data, if paramet-
ric conditions were provided the Bonferroni Modified test
was applied, otherwise the Mann-Whitney U-test was
used. All statistical tests were two-sided, with a threshold
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was carried out utilizing SPSS version 13.
Results
Coverage of the treatment target (PTV60 Gy and PTV46
Gy in the high-grade glioma plans) were essentially identi-
cal in the Standard IMRT, Sparing IMRT, and VMAT
plans, with the whole target receiving at least 95% of the
prescription dose (D100 95%). All IMRT and VMAT plans
were able to meet the constraints placed on the OAR, as
well as PTV. All plans were optimised to keep the max-
imum dose within the target to <110% of the prescription
dose (Dmax < 110%), and all plans were able to meet this
objective. The PTV coverage, conformality, and homogen-
eity were equivalent with VMAT and IMRT. Comparing
VMAT with all IMRT, maximum doses to the brainstem,
chiasm, left and right optic nerves, right eyes and lens
doses were similar. VMAT significantly reduced maximum
left eye and lens doses compared with standart IMRT and
sparing IMRT (p < 0.05). There was a statistically signifi-
cant difference noted between the three plans in terms of
monitor units (p < 0.05). The mean MU to treat a 2-Gy
fraction was 1472 (1041-1834) with standart IMRT, com-
pared with 1320 (1116-1993) sparing IMRT and with 994
(886-1150) VMAT. Lowest mean monitor unit value was
received in VMAT planning despite two arc. These dosi-
metric outcomes are shown in Table 3.
The lowest mean and max doses for the hippocampus
were found in the sparing IMRT planning, and this result
was statistically significant (p < 0.05). In V10, V20, V30, andTable 3 Dosimetric comparison of Standard IMRT plan, Sparin
Standard IMRT plan S
PTV46 max dose (Gy) 46.9 (46.2-47.4) 4
PTV46 mean dose (Gy) 48.9 (48-50.4) 4
D 95 46 (Gy) mean SD 46 (45.7-46.3) 4
PTV60 max dose (Gy) 63.2 (60.7-62.2) 6
PTV60 mean dose (Gy) 61 (61-64.3) 6
D 95 60 (Gy) 60 (59.7-60.2) 6
HI (60 Gy) 1.03 (1.02-1.05) 1
CI (60 Gy) 1.2 (1-1.4) 1
MU (0-60 Gy) 1472 (1041-1834) 1
Right lens max 4.8 (2.5-9.3) 5
Left lens max 7.7 (4.6-10.3) 6
Right eye mean 8.3 (4-25.8) 9
Left eye mean 10.8 (4.2-19.7 9
Right optic nerve max 35.1(29.2-41.0) 3
Left optic nerve max 36.1 (30.2-42.1) 3
Optic chiasm max 39.8 (33.7-45.6) 4
Brainstem max 51.1 (48.2-54.3) 5V40 dose values for the hippocampus in standard IMRT
planning, we observed a larger decrease in sparing planning
comparing to VMAT planning (Table 4), (Figure 1).
Discussion
Cognitive and endocrine dysfunctions are both important
and recognized problems after PBRT and complete brain
radiotherapy in pediatric as well as mature patients
(Merchant et al. 2005; Nandagopal et al. 2008; Kondoh
et al. 2003; Douw et al. 2009). Standard treatment includes
maximal safe surgical debulking and adjuvant radiotherapy,
with chemotherapy for high grade glioma. Better results of
glioma therapies with treatments in recent years make
these side effects more visible (Stupp et al. 2009). For this
reason, we should focus efforts to protect the cognitive
function in this cohort of patients.
This study aims to show preservation of the hippocam-
pus in high grade glioma patients during different plan-
ning techniques. In our study, we did not aim to preserve
the hippocampus in the same hemisphere with the tumor,
because in many cases the ipsilateral hippocampus is af-
fected by the tumor directly or by tumor edema indirectly.
Relapse risk is increased if the ipsilateral hippocampus is
protected in high grade gliomas (Chan et al. 2002). As is
known, relapses occur most often within two cm diameter
of tumor origin in high grade gliomas. This is one of the
main reasons for treatment failure as is shown in many re-
ports (Marsh et al. 2011). In addition, the hippocampus,
the limbic system, and neural stem cell compartments are
structures that are present bilaterally in human body.g IMRT plan and VMAT planfor PTV 46 and 60 plans
paring IMRT plan VMAT plan p value
7 (46.5-47.6) 47.5 (48.5-50.1) 0.14
9.3 (48.3-50.8) 48.5 (47.9-50.4) 0.21
6 (45.8-46.3) 46.4 (45.8-46.8) 0.55
3.4 (60.7-62.1) 63.6 (61.2-62.6) 0.44
1.2 (62.4-64.9) 61.4 (61.3-64.6) 0.23
0 (59.9-60.3) 60 (59.9-61.5) 0.65
.03 (1.02-1.04) 1.03 (1.02-1.04) 0.34
.2 (1.1-1.6) 1.2 (0.9-1.6) 0.48
320 (1116-1993) 994 (886-1150) 0.01
.2 (2.8-9.3) 7.5 (4.1-10.8) 0.1
.1 (3.8-9.8) 4.0 (3.7-9.9) 0.001
.4 (5.1-16.7) 10.3 (3.6-17.6) 0.45
.4 (6.2-16.2) 8.4 (5.9-16.3) 0.023
5.7 (30.6-40.8) 32.2 (25.2-39.1 0.65
7.9 (32.4-43.5) 33.2 (25.6-40.8) 0.55
3.2 (37.9-48.5) 37 (29.6-45.2) 0.7
0.9 (48.3-54.5) 50.1 (48.9-54.1) 0.44
Table 4 Comparison of hippocampus between mean,max,V10, V20, V30, and V40 doses
Standard IMRT Plan Sparing IMRT Plan VMAT plan p value
Hippocampus Mean dose (Gy) 32.4 15.07 17.2 0.001
Hippocampus Max Dose (Gy) 44.8 39.9 27.7 0.001
Hippocampus V10 mean dose (Gy) 100 80.4 92.4 0.002
Hippocampus V20 mean Dose (Gy) 98.9 17.3 38.7 0.001
Hippocampus V30 mean dose (Gy) 71.7 4.1 0 0.001
Hippocampus V40 mean (Dose Gy) 5 0.7 0 0.002
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itored in patients who have undergone temporal lobec-
tomy due to persistent epilepsy (Di Gennaro et al. 2006;
Giovagnoli et al. 2007). This gives rise to thought of one
normal medial temporal lobe is enough for normal mem-
ory function. Therefore in this dosimetric study, we aimed
to protect the contralateral hippocampus during PBRT.
The clinical tolerance of the hippocampus to radiation is
not well described but likely to vary according to patient
age, total dose, dose per fraction, time between fractions,
and the distribution of dose within it. Functional represen-
tation in the hippocampus of the dominant and non-
dominant hemispheres may not be interchangeable and
therefore the optimal dose constraint may change and not
simply depend on the laterality of the tumour. Johannesen
et al. (Johannesen et al. 2003) researched changes in white
matter using MRI scans of patients who received median
54 Gy cranial radiotherapy. According to the results of the
mentioned study, there were changes noted in the white
matter in T2 and FLAIR sequences of MRI above 29.2 Gy
doses, however there was no change between 12.5-27.5
Gy. Also, researchers noted a relationship between grade 3
white matter changes in MRI T2 and FLAIR sequences
with a lower quality of life as well as increase in sideFigure 1 Dose distrubutions and dose volume histograms.effects. In a pediatric study, Armstrong et al. (Armstrong
et al. 2010) identified a relationship between memory loss
and exposure of temporal lobe over 30 Gy. In a study con-
ducted in mature adults, it is reported that 40 Gy or more
exposure of brain leads to a change in the metabolic activ-
ity of the brain and effects neuro-cognitive functions
(Hahn et al. 2009).
In a dosimetric study that comparing treatment plans in
high grade gliomas while preventing contralateral hippo-
campus exposure, mean value for hippocampus in stand-
ard IMRT planning was 36.6 and it was found to be 15.8
Gy in sparing IMRT planning (Marsh et al. 2011). Another
dosimetric study in the same group of patients reported a
hippocampus mean value of 35.1 Gy, max dose 46.6 Gy in
standard IMRT planning, and a mean dose 19.7 Gy, max
dose 33.1Gy in sparing IMRT planning (Marsh et al. 2013).
In another study consisting of eighteen patients with grade
II and III glioma, the contralateral hippocampus mean dose
was reported as 24.9 Gy. Despite no clinical data identifying
optimal hippocampus mean dose, a dose between 15.8 and
24.9 Gy is generally considered for protecting neuro-
cognitive functions (Pinkham et al. 2013). In our study, only
sparing IMRT plan reached the determined mean and max
dose values for the contralateral hippocampus. In standart
Canyilmaz et al. SpringerPlus  (2015) 4:114 Page 6 of 7IMRT plan contralateral hippocampus mean dose was 32.4
Gy and max dose was 44.8 Gy, while in VMAT plan mean
dose was 17.2 Gy and max dose was 27.7 and in sparing
IMRT plan mean dose was 15 Gy and max dose was 39.9
Gy. When the literature is examined, hippocampus mean
dose values found in our study were lower compared to
other studies.
In a dosimetric study comparing IMRT and VMAT plan-
ning in high grade gliomas, at OARs doses in IMRT plan-
ning were similar to our study however were higher for
VMAT planning. In the same study, a reduction ratio of
doses received by risky organs in VMAT planning was
found statistically significant comparing to IMRT planning
(Shaffer et al. 2010). In our study we were unable to show
a statistically significant difference in doses received by at
OARs in all three plans. However, contralateral hippocam-
pus V10, V20, V30 and V40 dose values of the contralateral
hippocampus of standard IMRT planning provided more
reduction in sparing IMRT planning comparing to VMAT
planning. We chose two arc plans instead of one arc in our
study. In the two arc VMAT treatment plan, at OARs in-
cluding the hippocampus were exposed to more dosage in
comparison to other studies.
There was no statistically significant difference deter-
mined in regards to HI, CI, and PTV coverage. This data
is similar to reports by Shaffer et al. (Shaffer et al. 2010).
In the present study, monitor unit values of both IMRT
planning and VMAT planning were found higher. In that
study, seven fields for single PTV 60 in IMRT planning
and single arc for single PTV 60 in VMAT planning were
conducted (Shaffer et al. 2010). However in our study
seven fields with standard angles for PTV 46 in IMRT
planning and five fields identified according to tumor
localization for PTV 60 were conducted. This explains
higher mean monitor unit values in our study.Conclusion
This study aimed to show preservability of the hippocam-
pus in different treatment techniques for patients who re-
ceive partial brain radiotherapy for high grade gliomas.
While deciding for treatment plan of patients, the dose re-
ceived by at OAR should be considered as treatment plan
homogeneity. The lowest dose value for the hippocampus
was identified in sparing IMRT planning for this study.
This treatment plan can lower neuro-cognitive dysfunc-
tion, a late side effect of cranial radiotherapy. However,
this should be supported with further studies that show
the relationship between dose received by hippocampus
during PBRT in high grade gliomas and neuro-cognitive
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